제약 업계에서 전략적 우위를 확보하기 위해 RWE(Real-World Evidence)를 활용

This report delves into the strategic integration of real-world evidence (RWE) across the pharmaceutical lifecycle, highlighting its evolution from a supplementary data source to a critical driver of decision-making. It examines the growing regulatory acceptance of RWE, its role in health technology assessments and its impact on market access and reimbursement strategies. The report also addresses the challenges of post-marketing surveillance, the need for cohesive data ecosystems and the transformative potential of AI in RWE generation. Gain insights into building robust RWE capabilities and aligning evidence with payer needs to enhance strategic outcomes.

Key Questions Answered:

• 1. How can pharmaceutical companies leverage real-world evidence (RWE) for strategic advantage?
• 2. What is the strategic importance of RWE in the pharmaceutical industry?
• 3. How can RWE be effectively used in regulatory submissions?
• 4. In what ways does RWE influence health technology assessments?
• 5. How does RWE enhance market access and reimbursement strategies?
• 6. What role does RWE play in post-marketing surveillance?
• 7. What are the best practices for building robust RWE capabilities?
• 8. How are advances in analytical methods transforming RWE generation?
• 9. What challenges must be overcome to integrate RWE into pharma strategy?
• 10. How can companies align RWE with payer needs to unlock market access?

Key Companies:

Partial List of Participating Experts:

• Head of RWE Immunology, UCB, Belgium
• Associate Director, Clinical Strategy and Evidence Generation, global pharma company
• Head of Global Strategic Evidence and Communications, LEO Pharma, Denmark
• VP Medical & Regulatory, AstraZeneca, Germany
• Global Head Clinical Practice, Boehringer Ingelheim, Germany
• Vice President, Head of Global RWE and Digital Sciences, UCB, UK

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.